Clinical Trial Update: A Study of VAH631 in Patients With Essential Hypertension (Factorial Study) [Phase 3]

View source ↗

Summary

Phase 3 factorial study update of VAH631 in essential hypertension; the trial sponsored by Novartis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• VAH631

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED